Biolight Life Sciences Ltd. · TASE:BOLT
Biolight Life Sciences — Investor Presentation (October 2024)
25 slides from Biolight Life Sciences's investor presentation, Oct 14, 2024
Slide 1: Corporate Presentation
Corporate Presentation October 2024 * This is a translated version of Company’s corporate presentation in Hebrew as filed with the Israeli TASE on October 14, 2024 – created for convenience 1 purposes only.
Slide 2: Forward looking information
Forward looking information • This presentation was prepared by BioLight Life Sciences Ltd. (“BioLight") and contains summary information only. It does not include a detailed and/or complete description of BioLight, its subsidiaries, and holdings (collectively, the "Company"), its activities or fore
Slide 3: The only entity in Israel that invests solely in ophthalmic diseases
Click to edit Master title style The only entity in Israel that invests solely in the growing space of ophthalmic diseases 97Million ₪ Investment in Portfolio Companies 14 Million Current assets ₪ 7 2 Highly experienced Portfolio Management team and companies Exits scientific advisory committee As o
Slide 4: Holding Chart
Holding Chart* BioLight Life Sciences Ltd. Subsidiaries - Build to Partner Affiliate 56% 88% 76% 36% Strategic CSE listing in process collaborations Exits & royalties’ transaction VC approach - Held companies 92% 4% 5% 5% 8% Phase III Strategic investor *As of October 13, 2024 4
Slide 5: Highly Experienced Management Team
Highly Experienced Management Team Israel Makov Karin Gurevitz Chairman of the Board Yaacov Michlin Yifftach Biel Vice President, CEO CFO Legal Counsel 5
Slide 6: Scientific Advisory Board
Scientific Advisory Board Dr. Ron Neumann Prof. Anat Loewenstein Dr. Joseph Tauber Dr. Jeffrey Goldberg Dr. Vicente Anido Jr. BioLight’s Chief Medical Chairwoman of the Department of World-renowned authority in Professor and Chair of Served as the CEO of Aerie Officer (CMO), A leading Ophthalmology
Slide 7: Prevalence of eye diseases worldwide
Prevalence of eye diseases worldwide 340M Suffer from Dry eye syndrome 146M Suffer from Diabetic retinopathy 76M Suffer from Glaucoma 190M Suffer from Age-related Macular degeneration (AMD) And this is only a small sample from a variety of eye diseases that affect billions of individuals worldwide 7
Slide 8: Today's Challenges, Tomorrow's Solutions
Today’s Challenges • Aging population • Prevalence of eye disease rising • Insufficient eye doctors in relation to population growth • Fear of losing eyesight (blindness) Tomorrow’s Solutions • Early detection 75% • Better and personalized drugs • Improved devices for procedure and implants • Usage
Slide 9: Eye market growth forecast
Eye market growth forecast Average annual growth forecast for the eye market in the U.S. (drugs and medical device) Ophthalmology Markets U.S. Ophthalmic Drugs Market U.S Ophthalmic Devices market size. by drug class, 2020 - 2030 (USD Billion) size. by application. 2020 - 2030 (USD Billion) 6.5% U.S
Slide 10: The Product
The Product TeaRx technology is designed for the diagnosis of front-of-the-eye diseases by analyzing the composition of the tear fluid: • DiagnosTear product designed for diagnosing dry eye (CE approved and Israeli MOH approved) • DiagnosTear product designed for diagnosing Conjunctivitis (in clinic
Slide 11: The Challenge, The Solution, The Market
The Challenge Expected next year • An ophthalmologist or a primary care doctor must have effective, accurate tools for diagnosing front-of-the-eye diseases Share exchange, fund raising and listing on the Canadian Stock Exchange - funding The Solution mainly the Red Eye Product • Identification of Dr
Slide 12: The Product
The Product The insertion of a biodegradable sub-conjunctival implant for the slow and controlled release of a prescribed medication in a sustained manner for the treatment of glaucoma, inserted in the doctor's clinic once every few months (in an early clinical phase) 12
Slide 13: The Challenge, The Solution, The Market
Expected next year The Challenge A significant part of patients suffering from glaucoma are not complying • Fund raising with the medication treatment on a timely manner, causing an increase • Start human clinical trials in intraocular pressure and the progression of the disease which can lead to vi
Slide 14: The Products
The Products • A platform designed to deliver drugs to the retina aiming to reduce the need for injections • Eye drops containing high dosage of Cyclosporine finished a successful Phase I human clinical trial phase 14
Slide 15: The Challenge, The Solution, The Market
The Challenge Expected next year Increasing the penetrability and improving the tolerance of drug delivery Signed option to license to both the front and back of the eye with a global pharmaceutical company The Solution OphRx technology, based on nanostructures and liquid molecules enhances the deli
Slide 16: The Product
The Product Using innovative technology to identify Retinal Pathology vs. Healthy controls biomarkers within the tear fluid specific to a particular retinal disease (or in the early stage of the disease) to facilitate the development of quick and non-invasive Tear fluid sampling Proteomic Data NOVEL
Slide 17: The Challenge, The Solution, The Market
The Challenge Expected next year Considering the retina’s crucial role in light absorption, converting it into POC completion nerve signals, and the initial processing of the visual input, any disease Option for collaboration that impairs the function of the retina can lead to significant damage wit
Slide 18: The Product
The Product Developing solutions for diagnosing and monitoring the regression of peripheral vision using a personal computer and its build-in camera using eye-tracking 18
Slide 19: The Challenge, The Solution, The Market
The Challenge Expected next year Monitoring the regression of peripheral vision to improve treatment of Raise Funding and launch in Glaucoma Patients the USA The Solution Peripherex technology, based on invention of the head of Ophthalmology in Stanford and Israeli eye tracking technology provides a
Slide 20: Held Companies
Held Companies Company Summary Product Image Potential Received two FDA approvals for its AI product that was developed in combination with a desktop and handled camera for autonomous AEYE 8% Develops artificial intelligence (AI) solutions detection of moderate to severe diabetic for a variety of re
Slide 21: Summary of significant expected events next year
Summary of significant expected events next year • Share exchange, fund raising and listing on the Canadian Stock Exchange • Developing the Red Eye Product • Fund raising • Start human clinical trials Signed option to licenses with a global pharmaceutical company • POC completion • Option for collab
Slide 22: Investments compared to potential value
Investments compared to potential value* Invested in KNIS Market potential indicator Estimated market value of $14.8 million, subject to successful listing DiagnosTear 25,616 on the CSE (approximately NIS 56 million) Visci 36,570 As per actual investment amount Depending on future royalty proceeds p
Slide 23: Investments compared to potential value
Investments compared to potential value* Invested in KNIS Market potential indicator Actual proceeds received of approximately NIS 9 million and conditional future proceeds of approximately up to $10.8 million (c. NIS 40 million) in the coming Belkin 3,839 years based on Alcon sales milestones achie
Slide 24: Main Shareholders
Main Shareholders * Israel Makov 14% Public Dilip Shanghvi 39% 14% Rock One Institutional &>5% holders 19% 14% *As of September 30, 2024, as reported to the company 24
Slide 25: Thank You
THANK YOU E-mail: BioLight@bio-light.co.il Website: http://bio-light.co.il
BioLight Life Sciences — Investor Presentation (October 2024) on 6ix